ArticleMalaria journal2026
Sociodemographic and behavioral determinants of Plasmodium vivax-specific antibody responses among short-term Myanmar migrants in Thailand.
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Malaria serology for surveillance, insights into immunity, and vaccine development.Infection and immunity · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundMigrant populations from malaria-endemic countries pose challenges to elimination efforts in low-transmission settings. This study assessed Plasmodium vivax-specific antibody responses and associated sociodemographic and behavioral determinants among short-term Myanmar migrants in Thailand.
methodsA cross-sectional survey was conducted in March-April 2025 among 300 short-term Myanmar migrants in six malaria high-burden villages of Tha Song Yang District, Tak Province. Sociodemographic and behavioral data were collected via structured questionnaires. Finger-prick dried blood spots were collected to quantify IgG responses to eight P. vivax antigens using a multiplexed Luminex assay. Predicted recent exposure was defined using a previously developed and validated random forest classification algorithm, applying a 95% specificity threshold. Logistic regression models were used to identify factors associated with predicted recent exposure, while linear regression models examined associations with a composite antibody score representing overall seroreactivity across multiple antigens.
resultsAmong 294 PCR-negative participants, 104 (35.4%) were predicted as recently exposed. In multivariable logistic models, higher odds of predicted recent exposure were observed for age 30-39 years (aOR = 3.11, 95% CI 1.15-8.80), secondary education or above (aOR = 3.28, 95% CI 1.09-10.3), and Karen ethnicity (aOR = 3.68, 95% CI 1.42-10.0). Protective factors included seasonal (aOR = 0.28, 95% CI 0.08-0.95) and temporary work (aOR = 0.26, 95% CI 0.08-0.84), and income > 5,000 THB (aOR = 0.17, 95% CI 0.06-0.45). Exposure was also higher among those living > 15 min from a health facility (aOR = 2.07, 95% CI 1.00-4.43) and with negative malaria attitudes (aOR = 2.02, 95% CI 1.04-4.03). Higher composite antibody levels were observed among males (β = 1.17, 95% CI 0.07-2.28, p = 0.038), older participants (β = 0.12/year, 95% CI 0.08-0.17, p < 0.001), and agricultural workers (β = 2.58, 95% CI 0.01-5.14, p = 0.049). In contrast, higher income (β = - 3.83 per 10,000 THB, 95% CI - 6.28 to - 1.37, p = 0.002), longer stay (β = - 0.02/day, 95% CI - 0.04 to - 0.00, p = 0.025), and weekly returns to Myanmar (β = - 2.44, 95% CI - 4.14 to - 0.74, p = 0.005) were associated with lower antibody levels.
conclusionsAmong PCR-negative short-term migrants, one-third showed evidence of predicted recent P. vivax exposure. Antibody levels varied by demographic, occupational, and mobility-related factors, supporting the use of sero-surveillance to inform border elimination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.